

Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/09/2022
3.7 10/01/2022 1731714-00011 Date of first issue: 06/05/2017

SECTION 1. IDENTIFICATION

Product name : Moxifloxacin Liquid Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
 : Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Reproductive toxicity : Category 2

GHS label elements

Hazard pictograms : 

Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves, protective clothing, eye protection and face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical attention.
Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/09/2022
3.7 10/01/2022 1731714-00011 Date of first issue: 06/05/2017

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	>= 0.1 - <= 0.2

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Suspected of damaging the unborn child.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : No hazardous combustion products are known
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Moxifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
3.7	10/01/2022	1731714-00011	Date of first issue: 06/05/2017

Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Avoid inhalation of vapor or mist.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Gases

Moxifloxacin Liquid Formulation

Version 3.7 Revision Date: 10/01/2022 SDS Number: 1731714-00011 Date of last issue: 04/09/2022
 Date of first issue: 06/05/2017

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Moxifloxacin HCL	186826-86-8	TWA	1000 µg/m ³ (OEB 2)	Internal

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
Material

: Chemical-resistant gloves

Eye protection

: Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection
Hygiene measures

: Work uniform or laboratory coat.
 : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
 When using do not eat, drink or smoke.
 Wash contaminated clothing before re-use.
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Moxifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
3.7	10/01/2022	1731714-00011	Date of first issue: 06/05/2017

Appearance	:	liquid
Color	:	yellow
Odor	:	odorless
Odor Threshold	:	No data available
pH	:	4.1 - 4.6
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	1.0044 g/cm ³ (68 °F / 20 °C)
Solubility(ies)		
Water solubility	:	slightly soluble
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available

Moxifloxacin Liquid Formulation

Version 3.7 Revision Date: 10/01/2022 SDS Number: 1731714-00011 Date of last issue: 04/09/2022
Date of first issue: 06/05/2017

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:**Moxifloxacin HCL:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: positive

Test Type: Chromosome aberration test in vitro
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: in vitro micronucleus test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Application Route: Oral
Result: negative

Carcinogenicity

Not classified based on available information.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**Moxifloxacin HCL:**

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: LOAEL: 500 mg/kg body weight
Result: Effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

Moxifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
3.7	10/01/2022	1731714-00011	Date of first issue: 06/05/2017

Species: Monkey
 Application Route: Oral
 Developmental Toxicity: NOAEL: 10 mg/kg body weight
 Result: negative

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Intravenous injection
 Developmental Toxicity: LOAEL: 20 mg/kg body weight
 Symptoms: Skeletal malformations.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Components:

Moxifloxacin HCL:

Target Organs : Liver
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Moxifloxacin HCL:

Species : Rat
 LOAEL : 100 mg/kg
 Application Route : Oral
 Exposure time : 4 Weeks

Species : Rat
 NOAEL : 100 mg/kg
 Application Route : Oral
 Exposure time : 13 Weeks
 Target Organs : Liver
 Symptoms : Liver disorders

Species : Rat
 NOAEL : 20 mg/kg
 Application Route : Oral
 Exposure time : 6 Months
 Target Organs : Liver
 Symptoms : Liver disorders

Species : Monkey
 NOAEL : 50 mg/kg
 Application Route : Oral
 Exposure time : 4 Weeks

Moxifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
3.7	10/01/2022	1731714-00011	Date of first issue: 06/05/2017

Symptoms : No adverse effects.

Species : Monkey
 NOAEL : 15 mg/kg
 Application Route : Oral
 Exposure time : 13 Weeks
 Target Organs : Gastrointestinal tract
 Symptoms : Vomiting

Species : Monkey
 Application Route : Oral
 Exposure time : 26 Weeks
 Target Organs : Liver
 Symptoms : Liver disorders

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Moxifloxacin HCL:

Ingestion : Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
 Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
 If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

Moxifloxacin Liquid Formulation

Version 3.7 Revision Date: 10/01/2022 SDS Number: 1731714-00011 Date of last issue: 04/09/2022
 Date of first issue: 06/05/2017

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION
CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Reproductive toxicity**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.**US State Regulations****Pennsylvania Right To Know**

Water

7732-18-5

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION
Further information


SAFETY DATA SHEET



Moxifloxacin Liquid Formulation

Version 3.7 Revision Date: 10/01/2022 SDS Number: 1731714-00011 Date of last issue: 04/09/2022
Date of first issue: 06/05/2017

NFPA 704:



HMIS® IV:

HEALTH	*	0
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Moxifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
3.7	10/01/2022	1731714-00011	Date of first issue: 06/05/2017

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 10/01/2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8